Advertisement Intralytix, P&G to develop phage based technology - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Intralytix, P&G to develop phage based technology

Intralytix, a developer products for food safety, animal health and human therapeutics and probiotics, has signed multiple project collaboration agreement (MPCA) with The Procter & Gamble Company (P&G).

Under the deal, both the firms have agreed to collaborate on the development of bacteriophage (or phage) based technology for a range of applications.

Intralytix CEO John Woloszyn said their phage-based technology is all natural and environmentally friendly and they look forward to this collaboration bringing forth new innovations.

"The company already has two FDA/USDA approved phage-based products on the market: ListShield, effective at substantially reducing or eliminating Listeria monocytogenes on food products, and EcoShield, effective at substantially reducing or eliminating E. coli O157:H7 on red meat intended for grinding," Woloszyn said.